Healthcare Industry News: DeBakey VAD
News Release - October 4, 2007
MicroMed Cardiovascular Announces First DeBakey VAD(R) Implant at the Bakoulev Institute in MoscowHOUSTON, TX--(Healthcare Sales & Marketing Network)--Oct 4, 2007 -- MicroMed Cardiovascular, Inc. (OTC BB:MMCV.OB ) announced today that on Tuesday, October 2, 2007, doctors at the world famous Bakoulev Centre for Cardiovascular Surgery in Moscow, Russia successfully implanted the pediatric version of the DeBakey VAD® in a 17-year-old boy suffering from viral cardiomyopathy. Academician Professor Leo A. Bockeria stated, "The DeBakey VAD® is small and quiet and it immediately improved the patient's perfusion; it will greatly enhance his ability to survive and thrive." Also in the surgery was Professor Konstantin V. Shatalov who stated that "the implant was quite straightforward and the patient was extubated within two hours of the surgery. I am greatly encouraged by the results for our patients." "The staff at the Bakoulev Centre is excellent; I expect them to have great success with the device," said Dr. George Noon, of Baylor College of Medicine, who attended the implant.
This implant marks the first MicroMed DeBakey VAD® in the Russian market. "It is exciting to open this new market and provide our unique, life-saving technology to those adult and pediatric patients who can truly benefit from its use," said Robert Benkowski, CEO of MicroMed. The DeBakey VAD® provides an excellent therapy option for patients who are too sick to survive until a donor heart can be found or don't qualify for a donor heart.
About MicroMed Cardiovascular, Inc.
The DeBakey VAD® is a very small ventricular assist device (VAD) which was jointly developed by the famed heart surgeon Dr. Michael E. DeBakey, Dr. George Noon, and the National Aeronautics and Space Administration (NASA). The DeBakey VAD® is an implantable axial flow device designed to provide long term, improved quality of life for patients who suffer from severe heart failure. It is the only device that provides accurate, real-time flow measurement improving the clinicians' patient care. It is CE-Mark approved in Europe for Bridge-to-Transplant (BTT), Destination Therapy (DT), and pediatric use with the DeBakey VAD® Child. The DeBakey VAD® is undergoing an IDE BTT clinical study in the U.S. and the DeBakey VAD® Child is the only FDA approved (HDE) pediatric ventricular assist device. MicroMed Cardiovascular, Inc. trades on the over the counter bulletin board under the trading symbol MMCV.
Forward-looking statements in this release regarding MicroMed Cardiovascular, Inc. are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the company's products, increased levels of competition, new products and technological changes, the company's dependence upon third-party suppliers, intellectual property rights and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.
Source: MicroMed Cardiovascular
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.